That 2015 estimate by Irina at Cantor would equate to a ~$22M loss on, presumably, 47M f.d. shares. Irina was probably assuming that amount of loss would be the cashburn runrate, minus Vitaros royalties but plus a big price for taking Femprox thru trials and into launch, WITHOUT A PARTNER.
Yet APRI mgmt is clear that they will get partners for Femprox.
Irina likely won't change her financial scenario for 2015 until such partnership(s) have been inked and announced.
Market Data 
Markets 
AI
